Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) Associate Professor Imran Satia will give a poster presentation on the patient-reported outcomes from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with refractory chronic cough (RCC) , /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical ...